Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2022 Earnings Conference Call March 22, 2023 4:30 PM ET

Company Participants

Laurence Watts - Managing Director, Gilmartin Group LLC

Talat Imran - CEO

Svai Sanford - CFO

Mir Hashim - Chief Scientific Officer

Conference Call Participants

Brandon Folkes - Cantor Fitzgerald

Hao Shen - Bank of America

Andreas Argyrides - Wedbush

Annabel Samimy - Stifel

Ashwani Verma - UBS

Bert Hazlett - BTIG

Mitchell Kapoor - H. C. Wainwright

Operator

Hello, and welcome to Rani Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are a in a listen-only mode. Following management's prepared remarks, we'll hold a Q&A session. To ensure that we have ample time to adjust everyone's questions during the Q&A session, we'll ask for a limit of one question and one follow-up question per person. As a reminder, this call is being recorded today Wednesday, March 22, 2023.

I'd now like to turn the conference over to Laurence Watts of Gilmartin Group. Please go ahead, sir.

Laurence Watts

Thank you, operator. Joining us on the call today from Rani Therapeutics' are Chief Executive Officer, Talat Imran; Chief Financial Officer, Svai Sanford and Chief Scientific Officer, Mir Hashim.

During this call, management will make forward-looking statements that are subject to risks, uncertainties and assumptions such as but not limited to, those discussed in the risk factor section of the company's filings with the Securities and Exchange Commissions including its annual report on Form 10-K and quarterly reports on Form 10-Q, which identify the specific factors that may cause actual events or results differ materially from those described in these forward-looking statements. These things may include without limitation statements regarding product development and clinical trials, product potential, device progress and performance, potential impact on patients, the regulatory environment, manufacturing progress, certain business strategies, capital resources or operating performance. Actual results and the timing of events could differ materially from those projected in such forward-looking statements.

With that, I'll turn the call over to Talat Imran, Chief Executive Officer of Rani. Talat?

Talat Imran

Thank you, Laurence. Good afternoon everyone and thank you for joining our fourth quarter and full year 2022 financial results conference call.

I'm delighted to share the highlights of Rani Therapeutics' strong performance in 2022, during which the company achieved numerous milestone in the progression of its pipeline program and improvements in device performance. I would like to start by reviewing the important milestones that Rani achieved throughout the year.